Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2266)

[DasTier666]

Antwort auf Beitrag Nr.: 50.755.017 von Global-Player83 am 01.10.15 18:31:10

ich denke, dass Hillary Clintons Tweet schon einiges damit zu tun hat.
http://www.forbes.com/sites/steveschaefer/2015/09/21/hillary…

der IBB hat auch Federn lassen müssen

Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.

Novavax hat nach den zahlreichen guten Nachrichten aber immer noch "nur" Phantasie zu bieten und kein marktreifes Produkt. Es könnte also noch ein Stück abwärts gehen. Zumal die Marktkap immer noch bei ca. 1,9 Mrd. $ steht.

Ich bleibe aber trotzdem Long.

One tweet from Hillary Clinton sent these stocks into a tailspin, and now Wall Street thinks it's time to buy
By Bob Bryan October 3, 2015 8:22 AM
http://finance.yahoo.com/news/1-tweet-hillary-clinton-sent-1…

Warten wir's ab

[Global-Player83]

Und was sind nun die Gründe für diesen Absturz?

[DasTier666]

neue Präsentation auf der HP
http://novavax.com/presentation.show

-20% bei diesen Meldungen, unfassbar!

[DasTier666]

Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization

Bill & Melinda Gates Foundation to Support Development of the RSV F Vaccine Program
GAITHERSBURG, Md., Sept. 29, 2015

http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…



Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization


-RSV F Vaccine was safe and well-tolerated

-Significant anti-F, PCA and microneutralizing antibody responses elicited in mothers

-Efficient antibody transfer from mothers to infants observed

-Results suggest potential to protect infants when they are most at risk

GAITHERSBURG, Md., Sept. 29, 2015

http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…

[DasTier666]

Novavax Reports Second Quarter 2015 Financial Results
GAITHERSBURG, Md., Aug. 10, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults
GAITHERSBURG, Md., Aug. 10, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…

[DasTier666]

Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP
GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE)

http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…

[benny1981]

Heisse Aktie im Moment. Insbesondere interessant für Call-Schreiber Strategien (aufgrund der hohen Vola). I like that stock.


http://cnb.cx/1IeITwU

[DasTier666]

•Novavax Ebola/Makona Glycoprotein (GP) Nanoparticle Vaccine Candidate Update: NHP and Clinical Data
July 21, 2015

...Pending, ~ 24 July, neutralization data on same 100 serum panel from University of Marburg (Dr. Becker)

http://novavax.com/download/files/presentations/Novavax_EBOV…

[DasTier666]

Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference
GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE)

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.

The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points including days 28 and 35.

The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35. The adjuvanted single dose vaccine regimen induced GMEU between 1700 and 3400, representing a 21 to 27-fold rise over baseline at day 35.

“We are pleased to have the opportunity to share these positive data with the WHO. Novavax’ recombinant nanoparticle technology and proprietary Matrix-M adjuvant differentiates our Ebola GP Vaccine. The Phase 1 clinical data show that our vaccine was well-tolerated and elicited very high Ebola antibody responses,” said Gregory Glenn, M.D., Senior Vice President, Research and Development. “These data, together with two positive challenge studies in non-human primates, suggest that the Ebola GP Vaccine would be protective in humans.”

Stanley C. Erck, President and CEO said, “These positive data represent the third time Novavax has leveraged the power of our platform technology to rapidly address an emerging threat. These Ebola GP Vaccine data, in combination with clinical data from our H7N9 VLP vaccine candidate and preclinical data from our vaccine candidate for Middle East Respiratory Syndrome coronavirus, provide additional validation of our nanoparticle vaccine platform. Our Ebola GP Vaccine, adjuvanted with Matrix-M, was highly immunogenic at low doses, allowing for dose-sparing. Further, our recombinant vaccines do not need to be shipped or stored frozen, a key consideration for a vaccine developed against a novel lethal virus with pandemic potential.”

Today’s Novavax presentation to the WHO can be accessed via the Presentations section of the Novavax website, www.novavax.com by close of business today.

http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…

[DasTier666]

Die Homepage bekam eine Auffrischung und Gail Boudreaux steigt mit ins Boot. Meiner Meinung nach sind das nicht unbedingt Zeichen für schlechte Ergebnisse.


gabs hierzu ne Meldung?

BARDA Contract

...In June 2015, the contract was increased by $7.7 million to allow for the recovery of additional costs under the contract relating to the settlement of indirect rates for fiscal years 2011 and 2012. This additional amount was recorded as revenue in the three months ended June 30, 2015 and payment was received in July 2015.
http://novavax.com/page/16/barda-contract